DUTASTERIDE: A NEW 5‐ALPHA REDUCTASE INHIBITOR FOR MEN WITH LOWER URINARY TRACT SYMPTOMS SECONDARY TO BENIGN PROSTATIC HYPERPLASIA

Dutasteride is a new 5‐alpha reductase inhibitor for the treatment of men with moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. It has been available in the UK since March 2003. It is a competitive inhibitor of both type I and type II isoforms of the 5‐alpha reductase enzyme that converts testosterone to the more potent androgen, dihydrotestosterone. Randomised controlled studies have shown dutasteride to be statistically more effective than placebo in reducing lower urinary tract symptoms and increasing maximum urinary flow rates. This is a consequence of a reduction in serum dihydrotestosterone and hormone dependent prostate volume. Dutasteride has also been shown to decrease the absolute risk of urinary retention and the need for prostate‐related surgery when compared to placebo taken over a 24‐month period. In this review article we discuss the pharmacology and clinical effects of dutasteride, a new dual‐acting 5‐alpha reductase inhibitor.

• Publication year

  2003

• Venue

  International journal of clinical practice

• Publication date

  2003-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1742-1241.2003.tb10592.xPMID 14627182
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT Study)

  2005cited by this paper
• Effect of the dual 5 alpha-reductase inhibitor dutasteride on endocrine parameters and prostate volume

  2002cited by this paper
• The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.

  2002cited by this paper
• Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia.

  2002cited by this paper
• ASSESSMENT, DIAGNOSIS AND MANAGEMENT OF LOWER URINARY TRACT SYMPTOMS IN MEN

  2002cited by this paper
• Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia.

  2002cited by this paper
• Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.

  2002cited by this paper
• Impact of medical therapy on transurethral resection of the prostate: a decade of change.

  2001cited by this paper
• The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination.

  1999cited by this paper
• A Meta-Analysis on the Efficacy and Tolerability of α1-Adrenoceptor Antagonists in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction

  1999cited by this paper
• Some remarks on the epidemiology of acute urinary retention.

  1998cited by this paper
• A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α‐reductase inhibitors GI198745 and finasteride

  1998cited by this paper
• Androgen Metabolism and Prostate Cancer: Establishing a Model of Genetic Susceptibility

  1998cited by this paper
• The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia

  1998cited by this paper
• Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group.

  1998cited by this paper
• Long-Term Effects of Finasteride in Patients with Benign Prostatic Hyperplasia: A Double-Blind, Placebo-Controlled, Multicenter Study

  1998cited by this paper
• Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility.

  1998cited by this paper
• The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

  1998cited by this paper
• Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. Finasteride PSA Study Group.

  1997cited by this paper
• Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group.

  1997cited by this paper
• Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia.

  1997cited by this paper
• Using the ICSOoL to measure the impact of lower urinary tract symptoms on quality of life: evidence from the ICS-'BPH' Study. International Continence Society--Benign Prostatic Hyperplasia.

  1997cited by this paper
• Using the ICSQoL to measure the impact of lower urinary tract symptoms on quality of life: evidence from the ICS–‘BPH’ study

  1997cited by this paper
• Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study.

  1996cited by this paper
• Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials.

  1996cited by this paper
• Alpha1 adrenergic receptor blockade in the male lower urinary tract and other body systems.

  1995cited by this paper
• Design of the Prostate Cancer Prevention Trial (PCPT).

  1995cited by this paper
• New words for old: lower urinary tract symptoms for “prostatism”

  1994cited by this paper
• Urinary symptoms: prevalence and severity in British men aged 55 and over.

  1994cited by this paper
• Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia.

  1994cited by this paper
• Treatment of prostatic bleeding: suppression of angiogenesis by androgen deprivation.

  1993cited by this paper
• The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

  1992cited by this paper
• The effect of finasteride in men with benign prostatic hyperplasia.

  1992cited by this paper
• Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.

  1990cited by this paper
• The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study.

  1985cited by this paper
• The development of human benign prostatic hyperplasia with age.

  1984cited by this paper

• A concise review- Development of an analytical method and validation of dutasteride

  2025cites this paper
• Recent Advances in Drug Design and Drug Discovery for Androgen-Dependent Diseases

  2016influential citation
• A Method to Monitor Dutasteride in Rat Plasma Using Liquid-Liquid Extraction and Multiple Reaction Monitoring: Comparisons and Validation

  2014cites this paper
• Carbon–carbon double-bond reductases in nature

  2014cites this paper
• Advances in the design and discovery of drugs for the treatment of prostatic hyperplasia

  2013cites this paper
• An overview on 5alpha-reductase inhibitors.

  2010cites this paper
• NHG-Standaard Bemoeilijkte mictie bij oudere mannen

  2009cites this paper
• Stress Degradation Studies on Dutasteride and Development of a Stability-Indicating HPLC Assay Method for Bulk Drug and Pharmaceutical Dosage Form

  2008cites this paper
• Progesterone metabolites in breast cancer.

  2006cites this paper
• Dutasteride affects progesterone metabolizing enzyme activity/expression in human breast cell lines resulting in suppression of cell proliferation and detachment.

  2006cites this paper
• In situ androgen producing enzymes in human prostate cancer.

  2005cites this paper
• Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride.

  2005cites this paper
• Role of 5a-reductase inhibitors and selective estrogen receptor modulators as potential chemopreventive agents for prostate cancer.

  2005cites this paper
• Chemoprevention in prostate cancer.

  2004cites this paper
• Selective and rapid liquid chromatography-tandem mass spectrometry assay of dutasteride in human plasma.

  2004cites this paper
• A VALIDATED SPECTROPHOTOMETRIC METHOD FOR DETERMINATION OF DUTASTERIDE IN BULK DRUG AND PHARMACEUTICAL FORMULATIONS

  2003cites this paper